LibidonЛибидон
An oral peptide mixture made from calf prostate tissue, described in a Russian institute clinical report.
What the studies found
Comparison in people · 2011
Libidon: clinical report reproduced in the Russian institute-report collection (2011)
- Chronic prostatitis · mean urinary flow
- 23.5 vs 19.8 mL/sAdjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s.Adjunct arm marked p < 0.05 versus baseline.
- Benign prostatic hyperplasia · mean urinary flow
- 17.5 vs 14.2 mL/sShared baseline column 11.3 mL/s.Adjunct arm marked p < 0.05 versus baseline.
- Peak urinary flow
- 26.5 vs 24.4 mL/s in prostatitis and 20.5 vs 18.2 mL/s in hyperplasiaAdjunctive Libidon versus usual care.The report marks neither row as significant relative to baseline.
In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
More reported outcomes
- Reported adverse effects
- None describedSystematic monitoring and harms by arm are unavailable.
Study notes · methods, sources and limitations
Participants or model 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
Design 48 men received adjunctive Libidon (28 chronic prostatitis, 20 benign prostatic hyperplasia). Another 22 received usual care. Used uroflowmetry, symptoms and ultrasound.
Important limitations
- The signed original and protocol have not been authenticated. Allocation and blinding are not established; diagnostic subgroups, 22 separately described controls and symptom-specific denominators require reconciliation. Concurrent treatment prevents attribution to Libidon alone. No equivalence to Prostatilen or Prostamax is established.
- The tables give a single baseline per diagnostic group and do not state comparator subgroup counts. The significance markers do not test superiority over usual care.
Commercial brochure, PDF pages 47–50; institute original unauthenticated · Institute report — commercial reproduction
About Libidon
Identity / background source ↗
Research background
A prostate-derived peptide mixture described in a Russian institute-report reproduction. It is a distinct preparation from Prostatilen and the synthetic peptide Prostamax.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Commercial reproduction of an adjunct-treatment comparison; original unauthenticated
Study methods
Original preparation and study methods await verification
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
Russian reproduction and uroflowmetry tables checked. A separate report scan is linked.
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2011
Libidon: clinical report reproduced in the Russian institute-report collection (2011)
In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
Study notes and original source
Libidon: clinical report reproduced in the Russian institute-report collection (2011)
Prostate-derived peptide mixture · Institute report — commercial reproduction
Format: Russian PDF brochure · Reviewed: Methods and urinary flow tables checked in the Russian reproduction
Medical Center, St Petersburg Institute of Bioregulation and Gerontology (attributed in reproduction) · Commercial brochure, PDF pages 47–50; institute original unauthenticated
In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
Results and tables
Reported findings and study design
48 men received adjunctive Libidon (28 chronic prostatitis, 20 benign prostatic hyperplasia). Another 22 received usual care. Used uroflowmetry, symptoms and ultrasound.
Population or model 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
Dose, route and schedule
One 10 mg oral capsule twice daily with meals for 30 days alongside usual treatment. The comparator received usual treatment alone.
Protocol source ↗ · Russian institute-report reproduction, methods and Tables 1–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Chronic prostatitis · mean urinary flow | 23.5 vs 19.8 mL/s | Adjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline. |
| Benign prostatic hyperplasia · mean urinary flow | 17.5 vs 14.2 mL/s | Shared baseline column 11.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline. |
| Peak urinary flow | 26.5 vs 24.4 mL/s in prostatitis and 20.5 vs 18.2 mL/s in hyperplasia | Adjunctive Libidon versus usual care. · The report marks neither row as significant relative to baseline. |
| Reported adverse effects | None described | Systematic monitoring and harms by arm are unavailable. |
Tables 2–3 · uroflowmetry
| Measure | Baseline column | Usual care | Usual care + Libidon |
|---|---|---|---|
| Prostatitis · mean flow (mL/s) | 17.3 ± 1.2 | 19.8 ± 1.6 | 23.5 ± 2.4* |
| Prostatitis · peak flow (mL/s) | 22.1 ± 2.3 | 24.4 ± 2.1 | 26.5 ± 3.1 |
| Hyperplasia · mean flow (mL/s) | 11.3 ± 1.2 | 14.2 ± 1.4 | 17.5 ± 1.6* |
| Hyperplasia · peak flow (mL/s) | 16.1 ± 2.3 | 18.2 ± 1.9 | 20.5 ± 2.1 |
Asterisks indicate p < 0.05 versus baseline. The report does not identify the type of ± term.
The tables give a single baseline per diagnostic group and do not state comparator subgroup counts. The significance markers do not test superiority over usual care.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
- Source reviewed
- Russian institute-report reproduction, methods and Tables 1–3
Study limitations
- The signed original and protocol have not been authenticated.
- Allocation and blinding are not established; diagnostic subgroups, 22 separately described controls and symptom-specific denominators require reconciliation.
- Concurrent treatment prevents attribution to Libidon alone. No equivalence to Prostatilen or Prostamax is established.
Reviewed 2026-11-13.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗